sp-02l
Peripheral T-cell Lymphoma
Solasia Pharma K.K.Phase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 73/ 100
Competitive context
136 Active assets in the Peripheral T-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Tarapeutics Science Inc. | Phase 4 | BBB |
Inno-206 BeBetter Med Inc | Phase 4 | BBB |
Pralatrexate Peking University People's Hospital | Phase 4 | BBB |
Cyclophosphamide Tarapeutics Science Inc. | Phase 4 | BBB |
(+)-VINCRISTINE BeBetter Med Inc | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →